ASH 2023 preview – the first cell therapy winners
Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.
A short-lived hold for Arcellx & Gilead
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
